 |
AGENSYS NAMES DR. MARTHA VINCENT VICE PRESIDENT, CLINICAL RESEARCH AND DEVELOPMENT
SANTA MONICA, Calif., July 15, 2004 - Agensys, Inc. announced today the appointment of Martha Vincent, Ph.D., F.A.C.C.P. as Vice President, Clinical Research and Development. Dr. Vincent brings extensive expertise in clinical, regulatory and medical affairs to Agensys, a biotech company developing cancer antibody therapies. Dr. Vincent is joining Agensys from Amgen where she served in different clinical and medical affairs positions during her 17 year tenure, including Vice President, Clinical Research, Vice President, Clinical Development, and most recently as Vice President, Medical Affairs. Prior to joining Amgen in 1987, Dr. Vincent served as an Associate Director of Cardiovascular Clinical Research at Schering Plough. Dr. Vincent will lead the clinical development of Agensys' antibody products based on its portfolio of proprietary targets. "We are very pleased to have such an experienced clinical pharmacologist and accomplished executive join our management team" said Donald B. Rice, Chairman, President and CEO. "Dr. Vincent brings a wealth of expertise in clinical research and development that will add significantly to Agensys' capabilities for developing cancer therapeutics." About Agensys Agensys, Inc. is a privately held biotechnology company that is developing a pipeline of therapeutic monoclonal antibodies to treat solid tumor cancers. These antibodies, many of which are fully human, are being generated to a diverse portfolio of proprietary, clinically relevant cancer targets that encompass 14 types of solid tumors. The Company has the capabilities to both develop and manufacture antibody products and, through a partnership with Abgenix, has access to the XenoMouse® technologies required to generate fully human antibodies. In parallel to developing certain antibody products, Agensys aims to establish partnerships to develop and commercialize selected antibody products, and to exploit small molecule, vaccine, and diagnostic applications to its proprietary cancer targets. The Company's laboratories, GMP manufacturing facility and offices are located in Santa Monica, California. For further information about Agensys, please visit http://www.agensys.com. Contacts Donald B. Rice, Ph.D. President and CEO Agensys, Inc. 310.820.8029 x210 drice@agensys.com Aya Jakobovits, Ph.D. Senior Vice President and CSO Agensys, Inc. 310.820.8029 x216 ajakobovits@agensys.com << Back to Press Releases |